Inside a Probiotic Safety File: How a New Strain Proves Itself Safe
Everyone says their probiotic is safe. Almost no one shows the testing behind the claim. Here is what a complete strain safety file actually contains — with the real data behind the bacterium in our formula, published in a peer-reviewed journal.
The short version
- A well-known good flora organism like a typical lactobacillus has decades of consumption history behind it. A newly characterized strain has to build its file from zero.
- The core tests: genome sequencing and resistance screening, bacterial reverse mutation (Ames), micronucleus assays, and repeated-dose toxicity studies.
- For the Akkermansia muciniphila strain in our formula, those tests were published in Foods in 2024 — all negative for mutagenicity, genotoxicity and toxicity, with a no-observed-adverse-effect level (NOAEL) of 6.4×10¹¹ viable bacteria for a 70 kg adult [2].
- Safety data and efficacy claims are separate things. A clean file means the strain is reasonable to eat — it does not mean it treats anything.
Why new strains have to earn their place
Most of the bacteria marketed as good flora belong to genera with long food histories — yoghurt cultures, fermented vegetables, established probiotic dairies. When a regulator evaluates a supplement built on those organisms, centuries of consumption do most of the talking.
Akkermansia muciniphila is not that. It was first described in 2004 as a resident of the human gut microbiome that lives in the mucus layer [1], and it only reached commercial development in the last several years. Nobody has been eating it for centuries. That is why its safety has to be established the way a new food ingredient's safety is established — through a structured file of tests — and why anyone shopping for daily gut relief products containing novel strains should expect a brand to show that file.
Step 1 — Read the genome
Safety assessment now starts with whole-genome sequencing, because the genome predicts behavior. Reviewers look for two things: genes that could make the organism harmful (virulence factors, toxin genes) and genes that could make it resistant to antibiotics in ways it might pass on to nastier bacteria.
For our strain, the published analysis found exactly three potential antibiotic-resistance genes and one virulence-factor gene annotated across the whole genome [2]. That is a small number, and what matters more is what each one does — which is where the antibiotic testing comes in.
One natural resistance, tested for transfer
The strain is susceptible to five clinically important antibiotics (clindamycin, meropenem, tetracycline, chloramphenicol, ceftriaxone) and naturally resistant to one — moxifloxacin [2]. Natural resistance to a fluoroquinolone is not unusual; the safety question is whether that resistance can transfer to other gut bacteria. The researchers tested this directly with in vitro conjugation experiments: the moxifloxacin resistance did not transfer. That single experiment is the difference between "resistant" as a fact of the strain and "resistant" as a public-health concern.
If you are taking antibiotics or other medication, discuss any live-bacteria supplement with a qualified clinician or pharmacist before use.
Step 2 — What genome screening covers that older files missed
Genome-based screening also covers concerns that predate sequencing. A good example: shoppers looking for low histamine probiotics are usually reacting to the fact that some bacterial strains carry enzymes (histidine decarboxylases) that convert histidine into histamine — a genuine consideration for histamine-sensitive people. Historically you found this out by culture-and-see; today a sequenced genome can be checked for the gene directly. This is a real improvement in how histamine digest products and similar formulations can be screened before they ever reach a shelf — and a fair question to ask any brand: was your strain's genome checked for histamine-producing genes?
Step 3 — Mutagenicity: the Ames test and the micronucleus assay
Next comes genotoxicity — whether the organism, or its extracts, can damage DNA. Two complementary tests are standard:
- The bacterial reverse mutation (Ames) test uses specially engineered bacteria that only grow if a mutation reverses. More colonies than the spontaneous baseline means a mutagen. For our strain: negative across the tested conditions [2].
- The in vitro mammalian cell micronucleus test looks for broken chromosome fragments left outside the nucleus after cell division — a marker of chromosome damage. For our strain: negative [2].
These two assays are the same ones required for pharmaceuticals and food additives. A strain that passes both has no detectable interaction with DNA integrity at the tested doses.
Step 4 — Repeated-dose toxicity and the NOAEL
Genotoxicity tests ask about DNA. Toxicology studies ask a blunter question: what happens when a living organism eats this every day for weeks? Acute and sub-chronic toxicity studies for the strain found no adverse effects — no hematological or histopathological abnormalities — which allowed the researchers to state a NOAEL (no-observed-adverse-effect level) of 6.4×10¹¹ viable bacteria for a 70 kg individual [2]. That figure anchors the maximum daily servings regulators later accepted in filings.
Context for comparing categories: a soil based probiotic (often abbreviated SBO probiotic) built on spore-forming Bacillus species carries a different safety question — whether the strain carries toxin-production genes, which is exactly what its genome screen must rule out. Different organism classes, different headline risks, same underlying discipline: the file has to address the risks that class actually poses.
Step 5 — The manufacturing layer around the strain
A strain file covers the organism. The product adds a second layer: the factory. The supplier describes the following manufacturing certifications; original certificates are not reproduced on this page and should be independently checked:
| Layer | What it covers | Example from the file |
|---|---|---|
| Quality system | The factory's audited processes | ISO 22000, FSSC 22000, HACCP, NSF GMP |
| Batch testing | Every production lot against specifications | E. coli <10/g, mold ≤50/g, potency within spec, no visible impurities |
| Regulatory filing | The strain's use conditions | FDA NDI notification 1468: ≤170 mg/day (3.4×10¹⁰ TFU), 18+, not for pregnant/lactating women [5] |
One distinction worth memorizing: facility certifications and NDI filings are process assurances. They say the product is made under control and reasonable to consume. They say nothing about whether it works.
What a safety file cannot tell you
Clean data is not a health claim
Everything above establishes that the strain is reasonable to eat within its use conditions. None of it establishes that it treats, cures or prevents anything — safety testing is incapable of showing that, and any brand that borrows safety language to imply efficacy is doing something the data does not support. Two further limits: the NOAEL derives from animal toxicology and in vitro assays, which inform but do not replace human experience; and individuals differ — people with compromised immune systems, serious underlying conditions, or an injured gut barrier should talk to a physician before adding any live bacterial product, and published reviews note that as a resident mucus-degrader, Akkermansia specifically warrants that conversation in inflammatory bowel disease contexts [1][4].
Five questions that expose a brand's transparency
The market for gut health supplements ranges from rigorously documented to purely decorative. Five questions sort them fast — and a brand aiming for complete gut health transparency should be able to answer all five in one email:
- Is the strain identified to the number? "Akkermansia muciniphila" is a species; CGMCC No. 20955 is a strain with a file.
- Is the safety study published? Peer-reviewed publication lets you check the actual tables, not a summary of a summary [2].
- Was the genome screened for transferable resistance and toxin genes?
- Is there a current certificate of analysis per batch? Potency and contaminant lines, both.
- Do the use conditions appear on the label? Age minimums and pregnancy exclusions are not legal fine print — they come from the safety file, and omitting them breaks the chain between the data and the bottle.
The file behind our formula
The Akkermansia muciniphila strain in GLP-X +MAX is the subject of a published safety evaluation in Foods [2], an FDA New Dietary Ingredient notification [5], and a certified manufacturing system. Every milligram of the formula is on the label.*
See GLP-X +MAX →Common questions
What does NOAEL mean on a supplement dossier?
"No-observed-adverse-effect level" — the highest dose at which no harmful effect was seen in the toxicology studies. For this strain it is 6.4×10¹¹ viable bacteria for a 70 kg adult, which is far above a daily serving of any commercial product and anchors the maximum servings in regulatory filings.
Is a probiotic with antibiotic resistance dangerous?
Resistance itself is common and often harmless — what matters is whether it is natural to the strain and whether it can transfer to other bacteria. This strain's moxifloxacin resistance was tested in conjugation experiments and did not transfer.
Does "GMP certified" mean the product is proven safe?
GMP certification means the factory follows audited quality processes. It is an important layer of assurance, but it describes manufacturing control — not the strain's toxicology, and not effectiveness.
Who should not take Akkermansia?
The regulatory filings' conditions exclude pregnant and lactating women, and apply to healthy adults 18 and older. Anyone who is immunocompromised or managing a serious health condition should consult a physician first.
Where can I see the actual safety data?
For this strain, the core study is peer-reviewed and open to the public — the Foods 2024 paper cited below includes the Ames, micronucleus, antibiotic-resistance and toxicology tables. Ask any brand you buy from for the equivalent publications or certificates.
References
- Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol. 2004;54(Pt 5):1469–1476. doi:10.1099/ijs.0.02873-0. PMID 15388697.
- Ma X, Tian M, Yu X, Liu M, Li B, Ren D, Wang W. Characterization and Preliminary Safety Evaluation of Akkermansia muciniphila PROBIO. Foods. 2024;13(3):442. doi:10.3390/foods13030442. PMID 38338577.
- Hill C, Guarner F, Reid G, et al. The ISAPP consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–514. doi:10.1038/nrgastro.2014.66. PMID 24912386.
- Cani PD, Depommier C, Derrien M, Everard A, de Vos WM. Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms. Nat Rev Gastroenterol Hepatol. 2022;19(10):625–637. doi:10.1038/s41575-022-00631-9.
- FDA (R. Philip Yeager, Director, Division of Research and Evaluation). Response to New Dietary Ingredient Notification 1468 — Akkermansia muciniphila AKK PROBIO. May 20, 2026. Letter on file.
- EFSA Panel on Nutrition, Novel Foods and Food Allergens. Safety of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283. EFSA J. 2021;19(9):e06780. doi:10.2903/j.efsa.2021.6780.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
This article is educational and is not medical advice. It is not intended to diagnose, treat, cure or prevent any disease, and it is not a substitute for consultation with a qualified healthcare professional.
Toxicology data summarize studies conducted in vitro and in animals, as stated in the text and references. Manufacturing certificates were referenced in the supplier dossier but are not reproduced on this page.